



**Royal
Osteoporosis
Society**

Better bone health for everybody

Healthcare Industry Statement

The Royal Osteoporosis Society relies on donations to fund its work and partnerships with pharmaceutical companies and medical device manufacturers can help with the charity's vision to create a brighter future for people with fragile bones. We are proud though to be an independent charity which represents the voice of people affected by osteoporosis and fragility fractures. As such we have a robust statement which states how we work with pharmaceutical companies and medical device manufacturers.

- Any partnership must clearly support and align with our objectives. It must be in pursuit of our mission, with public good, patient benefit and welfare as the primary aims.

The charity will not recommend or explicitly endorse individual pharmaceutical products, medical devices or treatments.

- All partnerships must comply with the code of practice for the ABPI or ABHI
- The level of income the charity receives from pharmaceutical companies and medical device manufacturers is capped at 15%
- We strive to abide by the principles of independence, integrity and openness. In order to preserve this we do not approve relationships designed to give one pharmaceutical company or medical device manufacturer competitive advantage. Wherever possible we will seek a partnership composed of a minimum of two companies. Where this is not possible, each proposal will be assessed on a case-by-case basis.

Our annual income figure is published in our Financial Accounts.

A list of our Corporate Partners is available on our website and published in our Annual Review in the interest of transparency.

Approved 2014

Updated to Royal Osteoporosis Society on 5 February 2019

theros.org.uk